FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097800145> ?p ?o ?g. }

• W3097800145 endingPage "20" @default.
• W3097800145 startingPage "7" @default.
• W3097800145 abstract "Although adults with B-cell acute lymphoblastic leukemia (B-ALL) achieve high complete remission (CR) rates following treatment with intensive multi-agent chemotherapy regimens, up to two-thirds of these patients eventually relapse. Unfortunately, adults with relapsed or refractory (R/R) B-ALL have a poor prognosis, with variable responses to salvage chemotherapy regimens and allogeneic stem cell transplant. As such, the need to develop effective and well-tolerated treatments for this patient population has been of paramount importance over the past decade. In this regard, treatment options for R/R B-ALL patients have expanded considerably over a relatively short period of time, with the approvals of blinatumomab, inotuzumab ozogamicin and tisagenlecleucel occurring within only the past six years. Blinatumomab, a CD19 x CD3 bispecific T-cell engager (BiTE) was the first of these immune therapies to receive approval, and for many patients, is used as first-line salvage therapy. A number of large clinical trials have demonstrated improved progression-free survival and overall survival for R/R B-ALL patients receiving blinatumomab as compared to those receiving conventional salvage chemotherapy. In addition to being approved for both Philadelphia chromosome-negative and Philadelphia chromosome-positive R/R B-ALL, blinatumomab is also the only ALL therapy that carries approval for the treatment of measurable residual disease (MRD). Although blinatumomab has changed the therapeutic landscape for adults with R/R B-ALL, a number of important clinical considerations and questions remain, including the potential role of blinatumomab in the frontline setting, mechanisms of resistance, optimal goal MRD level, the role of transplant following MRD clearance, the optimal place for blinatumomab in the context of other recently approved immune-mediated therapies, and real world outcomes for patients treated outside the context of clinical trials. These issues are the focus of ongoing studies, which will hopefully inform future clinical practice regarding the utility of blinatumomab in the treatment of B-ALL patients." @default.
• W3097800145 created "2020-11-09" @default.
• W3097800145 creator A5017374388 @default.
• W3097800145 creator A5035192668 @default.
• W3097800145 creator A5044042347 @default.
• W3097800145 date "2020-11-01" @default.
• W3097800145 modified "2023-10-14" @default.
• W3097800145 title "<p>Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy</p>" @default.
• W3097800145 cites W1529239585 @default.
• W3097800145 cites W1701044074 @default.
• W3097800145 cites W1967348190 @default.
• W3097800145 cites W1988623079 @default.
• W3097800145 cites W1991644988 @default.
• W3097800145 cites W1996815863 @default.
• W3097800145 cites W2007234423 @default.
• W3097800145 cites W2031452426 @default.
• W3097800145 cites W2033439473 @default.
• W3097800145 cites W2038414910 @default.
• W3097800145 cites W2049000194 @default.
• W3097800145 cites W2076787465 @default.
• W3097800145 cites W2083494119 @default.
• W3097800145 cites W2104187048 @default.
• W3097800145 cites W2107925822 @default.
• W3097800145 cites W2109388187 @default.
• W3097800145 cites W2118241155 @default.
• W3097800145 cites W2127132803 @default.
• W3097800145 cites W2127742735 @default.
• W3097800145 cites W2135363598 @default.
• W3097800145 cites W2279127916 @default.
• W3097800145 cites W2329186770 @default.
• W3097800145 cites W2403074774 @default.
• W3097800145 cites W2516611622 @default.
• W3097800145 cites W2525034031 @default.
• W3097800145 cites W2527615464 @default.
• W3097800145 cites W2576962736 @default.
• W3097800145 cites W2591709377 @default.
• W3097800145 cites W2599899418 @default.
• W3097800145 cites W2607870782 @default.
• W3097800145 cites W2613210669 @default.
• W3097800145 cites W2725721905 @default.
• W3097800145 cites W2745344769 @default.
• W3097800145 cites W2755896474 @default.
• W3097800145 cites W2768556518 @default.
• W3097800145 cites W2787145330 @default.
• W3097800145 cites W2787301955 @default.
• W3097800145 cites W2808514046 @default.
• W3097800145 cites W2901031505 @default.
• W3097800145 cites W2905654455 @default.
• W3097800145 cites W2915133037 @default.
• W3097800145 cites W2931981435 @default.
• W3097800145 cites W2983205268 @default.
• W3097800145 cites W2987257811 @default.
• W3097800145 cites W2988511333 @default.
• W3097800145 cites W2988903265 @default.
• W3097800145 cites W2990608162 @default.
• W3097800145 cites W2993732448 @default.
• W3097800145 cites W3030846676 @default.
• W3097800145 cites W33007984 @default.
• W3097800145 cites W4242997939 @default.
• W3097800145 cites W4247121071 @default.
• W3097800145 doi "https://doi.org/10.2147/blctt.s223894" @default.
• W3097800145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7648528" @default.
• W3097800145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33173373" @default.
• W3097800145 hasPublicationYear "2020" @default.
• W3097800145 type Work @default.
• W3097800145 sameAs 3097800145 @default.
• W3097800145 citedByCount "15" @default.
• W3097800145 countsByYear W30978001452021 @default.
• W3097800145 countsByYear W30978001452022 @default.
• W3097800145 countsByYear W30978001452023 @default.
• W3097800145 crossrefType "journal-article" @default.
• W3097800145 hasAuthorship W3097800145A5017374388 @default.
• W3097800145 hasAuthorship W3097800145A5035192668 @default.
• W3097800145 hasAuthorship W3097800145A5044042347 @default.
• W3097800145 hasBestOaLocation W30978001451 @default.
• W3097800145 hasConcept C121332964 @default.
• W3097800145 hasConcept C126322002 @default.
• W3097800145 hasConcept C142424586 @default.
• W3097800145 hasConcept C143998085 @default.
• W3097800145 hasConcept C203014093 @default.
• W3097800145 hasConcept C2776694085 @default.
• W3097800145 hasConcept C2778020697 @default.
• W3097800145 hasConcept C2778461978 @default.
• W3097800145 hasConcept C2779823535 @default.
• W3097800145 hasConcept C2780775027 @default.
• W3097800145 hasConcept C2908647359 @default.
• W3097800145 hasConcept C2909962599 @default.
• W3097800145 hasConcept C71924100 @default.
• W3097800145 hasConcept C87355193 @default.
• W3097800145 hasConcept C99454951 @default.
• W3097800145 hasConceptScore W3097800145C121332964 @default.
• W3097800145 hasConceptScore W3097800145C126322002 @default.
• W3097800145 hasConceptScore W3097800145C142424586 @default.
• W3097800145 hasConceptScore W3097800145C143998085 @default.
• W3097800145 hasConceptScore W3097800145C203014093 @default.
• W3097800145 hasConceptScore W3097800145C2776694085 @default.
• W3097800145 hasConceptScore W3097800145C2778020697 @default.
• W3097800145 hasConceptScore W3097800145C2778461978 @default.

• next